Confirmatory analysis of the 13‐MD and ranking of its meta‐dimensions and items

Background:The 13‐MD is a new generic instrument developed to measure general health‐related quality of life(GHRQoL).This instrument considers all aspects of health(i.e.,physical,mental,and social)in a balanced way.A previous study led to minor changes in the original version of the 13‐MD.The objective of this study was to confirm the validity of the modified 13‐MD.Methods:Validity was assessed with recent data from the general population of Quebec,Canada.The meta‐dimensions and items composing the 13‐MD were also subjected to a ranking procedure,which allowed to determine the most important aspects for respondents.Results:A total of 1337 French‐speaking participants were recruited with 1099 completing the 13‐MD for validation purposes and 1084 completing the ranking procedure.The 13‐MD showed very satisfactory results and confirmed to be a valid instrument.The ranking of the meta‐dimensions revealed that“Well‐being”received the most points,followed by“Sleep and energy”and“Body functioning.”Conclusion:These results will be very useful in the continuous improvement of the 13‐MD,ultimately leading to the valuation stage(i.e.,development of a value set).

Economic Evaluation of Cervical Cancer Prevention Strategies in China

Objective To evaluate the economy of domestic bivalent human papilloma virus(HPV)vaccine,imported 9-valent HPV vaccine and 5 cervical cancer screening programs,and to provide a reference for relevant decision-making.Methods A Markov model of the natural disease development of cervical cancer was constructed to simulate the cumulative long-term cost and quality-adjusted life years(QALYs)of one hundred thousand healthy women after they received different interventions for cost-effectiveness analysis.Results and Conclusion Compared with the non-intervention group,the cost of per QALY obtained by two HPV vaccines and 5 screening programs ranged from 1117.56 yuan to 71660.48 yuan.Taking China’s GDP per capita in 2020 as the threshold,two HPV vaccines and 5 screening programs are cost-effective.Domestic bivalent vaccine is cost-effective and it should be introduced to the national immunization program in the future.Different screening programs are all cost-effective,too.Among them,careHPV test once every 5 years has the lowest ICER value and it can be used as the first choice for cervical cancer screening in rural areas or resource-limited areas in China.